Edesa Biotech Inc
Research Edesa Biotech Inc (EDSA) on Bullrun: market cap USD 42.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEDSA
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 42.87M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 4.22M
- Free cash flow-USD 7.53M
Valuation Snapshot
latest market cap is USD 42.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 7.19M | -USD 7.89M | n/a | -2.1 | USD 10.80M | USD 0 | USD 12.45M |
| FY2024 | USD 0 | -USD 6.17M | -USD 5.00M | n/a | n/a | USD 1.00M | USD 0 | USD 1.98M |
| FY2023 | n/a | -USD 8.37M | -USD 6.64M | n/a | -22.55 | USD 5.40M | USD 78.31K | USD 7.05M |
| FY2022 | n/a | -USD 17.55M | -USD 12.28M | n/a | n/a | USD 7.09M | USD 40.12K | USD 9.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 42.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 11.83M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.83M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 14.46M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 41.80M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 76.11M | n/a | n/a | n/a |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Edesa Biotech Inc's market cap?
Edesa Biotech Inc's market capitalization is USD 42.87M.
What does Edesa Biotech Inc do?
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.